Press Releases

Dr. Corinne Le Goff highlights clinical progress across the Company’s pipeline , p rovides context on the promise of DNA as a therapeutic and a vaccine LAWRENCEVILLE, N.J. , June 08, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc.   (NASDAQ: IMNN) , a clinical-stage drug-development company focused on

New data show continued durability of response over 14 months with humoral immune responses increasing over time LAWRENCEVILLE, N.J. , May 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc.   (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing non-viral DNA-mediated

Non-Viral DNA-Mediated Immunotherapy and Next-Generation Vaccine Programs with Multiple Near-Term Milestones Supported by a Strong Balance Sheet Conference Call Begins Today at 11:00 a.m. EDT LAWRENCEVILLE, N.J. , May 11, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc.

LAWRENCEVILLE, N.J. , May 04, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m.

Findings from a m ouse model of peritoneally disseminated ovarian cancer suggest biweekly dosing regimen for further evaluation in human clinical studies LAWRENCEVILLE, N.J. , April 19, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on

Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J. , March 30, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, today announced financial results

LAWRENCEVILLE, N.J. , March 23, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on developing DNA-mediated immunotherapy and next-generation vaccines, announces that the Company will host a conference call at 11:00 a.m.

Chief Science Officer describes compelling preclinical data supporting continued development of PLACCINE as a differentiated, next-generation vaccine modality LAWRENCEVILLE, N.J. , March 22, 2023 (GLOBE NEWSWIRE) -- IMUNON , Inc. (NASDAQ: IMNN) , a clinical-stage drug-development company focused on

LAWRENCEVILLE, N.J. , March 21, 2023 (GLOBE NEWSWIRE) -- Imunon , Inc. (NASDAQ: IMNN ), a clinical-stage drug development company focused on DNA-based immunotherapy and next-generation vaccines, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant

LAWRENCEVILLE, N.J. , March 15, 2023 (GLOBE NEWSWIRE) -- I MUNON , Inc.   (NASDAQ: IMNN ) , a clinical-stage drug development company, today announced that an abstract related to the Company’s DNA-based immunotherapy has been accepted for presentation at the American Association for Cancer Research